Results at median follow-up of 38 months
| . | ATG/CSA (%) . | Cy/CSA (%) . |
|---|---|---|
| Overall response | 13/16 (81) | 8/15 (53) |
| CR | 10 (63) | 6 (40) |
| PRi | 3 (18) | 2 (13) |
| Relapse | 6/13 (46) | 2/8 (25) |
| Cytogenetic evolution | 2/14 (14) | 1/12 (8) |
| . | ATG/CSA (%) . | Cy/CSA (%) . |
|---|---|---|
| Overall response | 13/16 (81) | 8/15 (53) |
| CR | 10 (63) | 6 (40) |
| PRi | 3 (18) | 2 (13) |
| Relapse | 6/13 (46) | 2/8 (25) |
| Cytogenetic evolution | 2/14 (14) | 1/12 (8) |
Overall responses are shown by type and overall percentage and do not differ between arms. Complete responses have been observed in 6 of 8 responders or 75% in the Cy arm and 10 of the 13 responders or 77% in the ATG arm (40% Cy and 63% ATG, overall complete response rates). No patients remain in the PRd response group. Relapse rates do not differ between arms (P = .38) with 6 among 13 responders and 2 among 8 responders relapsing in the ATG and Cy arms, respectively.